Parenteral formulations
AssigneeWyeth
InventorsJoseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
Life of this patent
Estimating the term…
Abstract
This invention provides parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779).
Claims30
A CCI-779 cosolvent concentrate which comprises, CCI-779, a parenterally acceptable solvent, and an antioxidant component.
A CCI-779 cosolvent concentrate which comprises, CCI-779, citric acid, and dehydrated ethanol.
A CCI-779 cosolvent concentrate which comprises, CCI-779, dehydrated ethanol, d,l-α-tocopherol, and propylene glycol.
A parenteral formulation which comprises CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant.
A process for preparing a parenteral CCI-779 formulation which comprises
- (a) mixing CCI-779 with a parenterally acceptable solvent and an antioxidant component to provide a cosolvent concentrate;
- (b) mixing a diluent solvent and a surfactant to produce a diluent;
- and
- (c) mixing the cosolvent concentrate with the diluent to provide the CCI-779 parenteral formulation.
Dependencies are inferred from the claim text.